Anaphylaxis
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
Leaflet BERIATE 1000UI powder and solvent for solution for injection / infusion
- Product code:
- W61672001
- Quantity:
- 1
- Indicated for:
- bleeding; coagulation disorders
- Route of administration:
- injectable / infusion
- Substance:
- coagulation factor VIII (coagulation factor)
- ATC
- B02BD02 — Blood and blood forming organs | Vitamin k and other hemostatics | Blood coagulation factors
Precautions:
Additional monitoring
This medicine is subject to additional monitoring.
Refrigerated storage
Store in the refrigerator as instructed in the leaflet.
Coagulation factor VIII is an essential protein for the blood clotting process, playing a key role in forming the clot that stops bleeding. A deficiency of factor VIII causes hemophilia A, a hereditary disease characterized by spontaneous or prolonged bleeding. Treatment with factor VIII is vital for preventing and controlling these bleeding episodes.
Factor VIII is administered intravenously under medical supervision, with the dose determined by the severity of the deficiency and the type of bleeding. Treatment can be given prophylactically or as needed, for example during surgeries or after injuries.
Side effects may include allergic reactions, fever, headaches, or, rarely, the development of antibodies that can reduce the effectiveness of the treatment. Careful monitoring of the patient is essential to quickly detect any adverse reactions and adjust the treatment if necessary.
Therapy with factor VIII has significantly improved the quality of life for people with hemophilia A. Following medical advice and being informed about possible risks contribute to safe and effective treatment.
Factor VIII is administered intravenously under medical supervision, with the dose determined by the severity of the deficiency and the type of bleeding. Treatment can be given prophylactically or as needed, for example during surgeries or after injuries.
Side effects may include allergic reactions, fever, headaches, or, rarely, the development of antibodies that can reduce the effectiveness of the treatment. Careful monitoring of the patient is essential to quickly detect any adverse reactions and adjust the treatment if necessary.
Therapy with factor VIII has significantly improved the quality of life for people with hemophilia A. Following medical advice and being informed about possible risks contribute to safe and effective treatment.
General data about BERIATE 1000UI
- Substance:
- coagulation factor VIII
- Date of latest medicines list:
- 01-06-2026
- Product code:
- W61672001
- Concentration:
- 1000UI
- Pharmaceutical form:
- powder and solvent for solution for injection / infusion
- Quantity:
- 1
- Product type:
- Original
- Price:
- 2503.26 RON
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for coagulation factor VIII
Concentrations available for coagulation factor VIII
- 1000UI
- 100UI/ml
- 2000UI
- 200UI/ml
- 250UI
- 500UI
- 50UI/ml
Compensation lists for BERIATE 1000UI CSL Behring
NHP 6.1 (C2) - Hemophilia and thalassemia
- Price
- 2503.26 RON
- Copayment
- 1907.63 RON
- Patient
- 595.63 RON